化疗与后程加速超分割联合治疗食管癌临床观察

目的评价化疗联合后程加速超分割放射治疗食管癌的疗效.方法70例食管癌患者,随机分为2组,化放组36例,单纯放疗组34例.放疗采用60Co γ线外照射,先前一后二野等中心照射40 Gy后改用后程加速超分割放疗,(2次/d,1.5 Gy/次),全疗程总剂量共67～70Gy,化疗采用5-FU CF DDP.结果化放组与单放组1、3、5年生存率分别为71.0%、51.6%、29.1%和48.1%、30.0%、10.2%,两组对比差异有显著性(P＜0.05)结论化疗加后程加速超分割治疗食管癌能提高生存率,患者容易耐受.

Analysis of the curative effect of chemotherapy plus late course hyperfractionated accelerated radiotherapy for esophageal carcinoma

Objective To evaluate the effect of chemotherapy plus late course hyperfractionated accelerated radiotherapy (LCHART) for esophageal carcinoma. Methods Seventy patients with esophageal carcinoma were randomized into two groups. Thirty six patients received chemotherapy plus radiotherapy(CT-RT) , 34 received radiotherapy(RT). All patients were firstly given with y-ray, total tumor dose was 40Gy/20F, with conventional fractionation regimen and followed by 1. 5Gy LCHART, twice daily. The total dose varied up to 67-70Gy, chemotherapy regimen was FD(5-Fu,CF and DDP). Results One-, three-and five-year survival rate in CT-RT group and RT group were 71. 0% ,51. 6% ,29.1 % and 48. 1 % ,30. 0% , 10. 2% respectively (P <0. 05). Conclusion Chemotherapy plus LCHART can increase the survival rate in patients with esophageal carcinoma.